Thera Neuropharma is advancing an innovative approach that employs two complementary technologies.

Our small molecule regenerative therapy (SMRT) and self-delivering RNA interference (sd-rxRNA®) technology platforms are uniquely positioned to modulate cell functioning, regenerative processes, and RNA activity in the central nervous system.

The lead candidates leverage the activation of a key CNS pathway and modulate cell energy mechanisms. These molecules maintain brain cell viability and regenerate the brain network with a potentially disease-modifying and curative effect.